Chiesi Expands Its Rare Disease Reach With $1.48bn Amryt Buyout
US Expansion Also Part Of Strategy
The privately owned company currently earns most of its revenues in respiratory medicine in Europe, but has set its sights on expanding in rare diseases and the US market.
